Abstract: The present invention provides pharmaceutical compositions and methods for use and manufacture thereof. The pharmaceutical compositions comprise a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt or solvate thereof and an amphiphilic copolymer comprising at least one hydrophilic component and at least one hydrophobic component. The cannabinoid is encapsulated in the amphiphilic copolymer, and the composition is suitable for intranasal or inhalation delivery.

Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce A? protein levels; (ii) reduce A? aggregation: (iii) maintain A?PP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3? protein; (vi) decrease GSK-3? protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Abstract: The present application relates to compositions comprising (i) THC; (ii) melatonin; and (iii) insulin and methods of using same to Alzheimer's disease in a subject in need thereof without the psychological impairment and side effects associated with THC.

Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i)reduce A? expression; (ii) reduce A? aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3? protein; (vi) decrease the expression of GSK3? protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce A? protein levels; (ii) reduce A? aggregation: (iii) maintain A?PP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3? protein; (vi) decrease GSK-3? protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Abstract: Provided herein are compounds, compositions, pharmaceutical compositions, kits, and methods relating to novel sulfono-?-AA peptides. Novel sulfono-?-AA peptides as described herein can have the structure according to Formula 1: In embodiments according to the present disclosure, novel sulfono-?-AA peptides as described herein have minimal toxicity, can repair neuronal damage, inhibit Amyloid beta aggregation, and promote cellular growth and viability.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: Disclosed herein are exogenous antigen sensitized immature dendritic cells. The dendritic cell may also be dead. The exogenous antigen sensitized immature dendritic cells may be used to elicit an increased immune response. Further provided are vaccines comprising the exogenous antigen sensitized immature dendritic cells, methods, of inducing an immune response in a patient, and methods of treating a disease.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, inhibiting, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, inhibiting, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.

Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.

Abstract: A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ?300-3,000 MHz) for a predetermined absorption period (preferably greater than ?3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W/kg. The methodology enhances cognition in the subject and/or treats/prevents the underlying neurological disorder or a symptom thereof.

Abstract: Embodiments of the present disclosure provide for ?-AApeptides, ?-AApeptide building blocks, methods of making ?-AApeptides and libraries of ?-AApeptides, methods of screening the ?-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for ?-AApeptides that are inhibitors of A? peptide aggregation, methods of inhibiting and disassembling A? peptide aggregation, methods of inhibiting the toxicity of A? aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.

Abstract: Embodiments of the present disclosure provide for ?-AApeptides, ?-AApeptide building blocks, methods of making ?-AApeptides and libraries of ?-AApeptides, methods of screening the ?-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for ?-AApeptides that are inhibitors of A? peptide aggregation, methods of inhibiting and disassembling A? peptide aggregation, methods of inhibiting the toxicity of A? aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.